Navigation Links
Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
Date:10/29/2008

Franklin's Experience to Bring Growth and Leadership

CARY, N.C., Oct. 29 /PRNewswire/ -- Cornerstone Therapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today announced that Josh Franklin has joined the company as vice president, Marketing.

Craig Collard, Cornerstone's president and chief executive officer, welcomed Franklin to the company, noting that "Josh's skills in pharmaceutical brand management and his leadership experience in a growth environment will be key as Cornerstone transitions into a publicly-held company." As announced in May Cornerstone plans to go public through a merger with Critical Therapeutics (Nasdaq: CRTX), which is scheduled to close in Q4 2008.

Before his Cornerstone appointment, Franklin was a key member of the marketing team at St. Louis, Mo.-based Ther-Rx Corporation (a subsidiary of KV Pharmaceutical) during a critical five-year growth period, serving most recently as vice president, Marketing. In previous positions, Franklin filled marketing roles with Biovail Pharmaceuticals and Ross Products Division, Abbott Labs. In these positions, he launched and managed products throughout various lifecycle phases in multiple therapeutic categories.

"I know I'm joining Cornerstone at a pivotal time," said Franklin, returning to North Carolina for the second time in his career. "And, I'm looking forward to helping lead not only the evolution of products and processes but also the company itself as our organization elevates to the next level."

A U.S. Army veteran, Mr. Franklin holds a B.S. in Business Administration from Methodist University, and M.H.A. and M.B.A. degrees from The Ohio State University.

ABOUT CORNERSTONE THERAPEUTICS, INC.

Cornerstone BioPharma Holdings, Inc., located in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. Cornerstone currently promotes four marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone's commercial strategy is to acquire non-promoted or underperforming branded pharmaceutical products and then maximize their potential value by promoting the products using its sales and marketing capabilities and applying various product life cycle management techniques. Cornerstone's product development pipeline consists of three line extensions of one of its currently marketed products and three other product candidates for the respiratory market. Cornerstone also generates revenue from the sale of six marketed product lines that include products that it does not promote.


'/>"/>
SOURCE Cornerstone Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
5. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
6. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
7. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
8. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
9. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
10. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
11. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Wilderness Voices”: ... of world travel. “Wilderness Voices” is the creation of published author, Martha McKown, ... Martha McKown was inspired as a very young child when her older sisters studied ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... Stewart is the Founder and Managing Member for t4 Leadership Development & Consulting. ... critical to his definition of “success”: physician leadership development, servant leadership, data driven ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... PracticeMatch, a ... to help healthcare employers connect with physicians and advanced practitioners like nurse practitioners ... career fairs in August through November of this year. The online career fairs ...
(Date:8/21/2017)... , ... August 21, 2017 , ... FCPX LUT Monochromatic ... Editors can quickly and easily add washed color grades to footage. A LUT is ... changes every pixel’s color to the corresponding color indicated by the table. This pack ...
(Date:8/21/2017)... ... August 21, 2017 , ... Duncan Insurance Agency ... the people of Michigan. The new initiative fundraises for the Kalamazoo Humane Society ... forefront of animal protection and welfare by addressing the root causes of pet ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/4/2017)... The search for test results that can ... has long been the goal of healthcare providers and ... the largest meeting of lab professionals and IVD firms ... firm Kalorama Information.  The firm said scores of companies ... supplies and software were at the American Association for ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital ... services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... that uses UVC light energy to kill deadly pathogens such as C. diff , ... Tru-D SmartUVC ... Tru-D in action in a patient ...
Breaking Medicine Technology: